Alembic Pharmaceuticals Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 15, 2026

Key Highlights

The Latest Trading Price of Alembic Pharmaceuticals Ltd is ₹ 743.1 as of 12 Jun 15:30 . The P/E Ratio of Alembic Pharmaceuticals Ltd changed from 16.5 on March 2021 to 31.3 on March 2025 . This represents a CAGR of 13.66% over 5 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 years The Market Cap of Alembic Pharmaceuticals Ltd changed from ₹ 18971 crore on March 2021 to ₹ 18265 crore on March 2025 . This represents a CAGR of -0.76% over 5 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 years The revenue of Alembic Pharmaceuticals Ltd for the Mar '26 is ₹ 1874 crore as compare to the Dec '25 revenue of ₹ 1891 crore. This represent the decline of -0.92% The revenue of Medicamen Biotech Ltd for the Mar '26 is ₹ 62.38 crore as compare to the Dec '25 revenue of ₹ 47.44 crore. This represent the growth of 31.49% The ebitda of Alembic Pharmaceuticals Ltd for the Mar '26 is ₹ 229.77 crore as compare to the Dec '25 ebitda of ₹ 264.93 crore. This represent the decline of -13.27% The ebitda of Medicamen Biotech Ltd for the Mar '26 is ₹ 7.18 crore as compare to the Dec '25 ebitda of ₹ 4.91 crore. This represent the growth of 46.23% The net profit of Alembic Pharmaceuticals Ltd changed from ₹ 134.54 crore to ₹ 201.53 crore over 8 quarters. This represents a CAGR of 22.39% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 4.45 crore over 8 quarters. This represents a CAGR of 135.85% The Dividend Payout of Alembic Pharmaceuticals Ltd changed from 25.09 % on March 2021 to 42.97 % on March 2025 . This represents a CAGR of 11.36% over 5 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 years .

About Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited manufactures and markets generic pharmaceutical products all over the world.
The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Limited was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Limited.
The company is engaged in pharmaceuticals business.
As per the Scheme of Arrangement, the 'Pharmaceutical Undertaking' of Alembic Limited got demerged and transferred to the Company with effect from April 1, 2010. In April 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of Alembic Pharmaceuticals Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Alembic Pharmaceuticals Ltd or Medicamen Biotech Ltd?

Market cap of Alembic Pharmaceuticals Ltd is 14,606 Cr while Market cap of Medicamen Biotech Ltd is 311 Cr

What are the key factors driving the stock performance of Alembic Pharmaceuticals Ltd and Medicamen Biotech Ltd?

The stock performance of Alembic Pharmaceuticals Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alembic Pharmaceuticals Ltd and Medicamen Biotech Ltd?

As of June 15, 2026, the Alembic Pharmaceuticals Ltd stock price is INR ₹743.1. On the other hand, Medicamen Biotech Ltd stock price is INR ₹229.45.

How do dividend payouts of Alembic Pharmaceuticals Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Alembic Pharmaceuticals Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.